NASDAQ:LENZ LENZ Therapeutics (LENZ) Stock Price, News & Analysis $3.58 -0.21 (-5.54%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$3.66 +0.09 (+2.37%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About LENZ Therapeutics Stock (NASDAQ:LENZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LENZ Therapeutics alerts:Sign Up Key Stats Today's Range$3.51▼$3.8450-Day Range$3.58▼$5.9652-Week Range$3.51▼$49.85Volume1.13 million shsAverage Volume710,227 shsMarket Capitalization$112.48 millionP/E RatioN/ADividend YieldN/APrice Target$28.80Consensus RatingModerate Buy Company Overview LENZ Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for people with presbyopia, an age-related condition that reduces the eye’s ability to focus on near objects. The company’s lead product is VIZZ (aceclidine hydrochloride ophthalmic solution), a prescription eye drop designed to improve near vision by creating a pinhole effect through pupil modulation while aiming to preserve distance vision. In July 2025, the U.S. Food and Drug Administration approved VIZZ for the treatment of presbyopia in adults. The approval marked the company’s transition from a clinical-stage developer to a commercial ophthalmology company. LENZ is focused on making VIZZ available to patients and eye-care professionals in the United States and may pursue additional regulatory and commercial opportunities in other geographies. LENZ Therapeutics was established to address unmet needs in the treatment of presbyopia and is headquartered in San Diego, California. The company is led by Chief Executive Officer Eef Schimmelpennink, who has experience in the pharmaceutical and ophthalmology industries. Its shares trade on the Nasdaq under the symbol LENZ.AI Generated. May Contain Errors. Read More LENZ Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreLENZ MarketRank™: LENZ Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 555th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingLENZ Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialLENZ Therapeutics has a consensus price target of $28.80, representing about 704.5% upside from its current price of $3.58.Amount of Analyst CoverageLENZ Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about LENZ Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for LENZ Therapeutics are expected to grow in the coming year, from ($4.18) to ($3.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LENZ Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LENZ Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLENZ Therapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about LENZ Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted36.89% of the float of LENZ Therapeutics has been sold short.Short Interest Ratio / Days to CoverLENZ Therapeutics has a short interest ratio ("days to cover") of 14.55, which indicates bearish sentiment.Change versus previous monthShort interest in LENZ Therapeutics has recently decreased by 2.25%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLENZ Therapeutics does not currently pay a dividend.Dividend GrowthLENZ Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for LENZ Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for LENZ on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders8.30% of the stock of LENZ Therapeutics is held by insiders.Percentage Held by Institutions54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENZ Therapeutics' insider trading history. Receive LENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LENZ Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZOctober 1 at 10:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZSeptember 29, 2026 | globenewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)LENZ Therapeutics: Below Cash For A ReasonSeptember 25, 2026 | seekingalpha.comLENZ Therapeutics, Inc. (LENZ) Stock Price, News, Quote & History - Yahoo FinanceSeptember 25, 2026 | finance.yahoo.comLENZ Therapeutics (LENZ)September 24, 2026 | es.investing.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZSeptember 24, 2026 | prnewswire.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Moderate Buy" by AnalystsSeptember 23, 2026 | americanbankingnews.comSee More Headlines LENZ Stock Analysis - Frequently Asked Questions How have LENZ shares performed this year? LENZ Therapeutics' stock was trading at $16.00 at the start of the year. Since then, LENZ shares have decreased by 77.6% and is now trading at $3.58. How were LENZ Therapeutics' earnings last quarter? LENZ Therapeutics, Inc. (NASDAQ:LENZ) announced its quarterly earnings results on Tuesday, August, 11th. The company reported ($1.02) EPS for the quarter, topping analysts' consensus estimates of ($1.05) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to analysts' expectations of $2.38 million. LENZ Therapeutics had a negative trailing twelve-month return on equity of 53.39% and a negative net margin of 586.74%. Read the conference call transcript. When did LENZ Therapeutics IPO? LENZ Therapeutics (LENZ) raised $224 million in an initial public offering on Thursday, June 24th 2021. The company issued 14,000,000 shares at a price of $15.00-$17.00 per share. How do I buy shares of LENZ Therapeutics? Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LENZ Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LENZ Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings8/11/2026Today10/02/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (11m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 LENZ's financial health is in the Red zone, according to TradeSmith. LENZ has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:LENZ Previous SymbolNASDAQ:LENZ CIK1815776 Webwww.lenz-tx.com Phone(858) 925-7000FaxN/AEmployees152Year Founded2013Price Target and Rating Average Price Target for LENZ Therapeutics$28.80 High Price Target$50.00 Low Price Target$7.00 Potential Upside/Downside+704.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($4.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$82.13 million Net Margins-586.74% Pretax Margin-586.72% Return on Equity-53.39% Return on Assets-49.14% Debt Debt-to-Equity RatioN/A Current Ratio13.55 Quick Ratio13.31 Sales & Book Value Annual Sales$19.09 million Price / Sales5.89 Cash FlowN/A Price / Cash FlowN/A Book Value$9.09 per share Price / Book0.39Miscellaneous Outstanding Shares31,420,000Free Float28,812,000Market Cap$112.48 million OptionableN/A Beta0.64 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:LENZ) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
